MRTX: Mirati Therapeutics, Inc. Stock

by  •  • Comments Off on MRTX: Mirati Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) n/a
Enterprise Value ($M) n/a
Book Value ($M) n/a
Book Value / Share n/a
Price / Book n/a
NCAV ($M) 0.00
NCAV / Share n/a
Price / NCAV n/a

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) n/a
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio n/a
Current Ratio n/a

Balance Sheet (mrq) ($M)
Current Assets n/a
Assets n/a
Liabilities n/a
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue n/a
Operating Income n/a
Net Income n/a
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations n/a
Cash from Investing n/a
Cash from Financing n/a

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Armistice Capital, Llc 0.71 -85.67
02-14 13G/A Avoro Capital Advisors LLC 7.00 -12.04
02-14 13G Baker Bros. Advisors Lp 0.00 -100.00
02-14 13G/A Rtw Investments, Lp 0.00 -100.00
02-13 13G/A Vanguard Group Inc 7.57 6.69
02-09 13G Morgan Stanley 8.70
02-08 13G/A Wellington Management Group Llp 0.00 -100.00
01-31 13G BlackRock Inc. 5.50 40.25
01-25 13D/A Boxer Capital, LLC 0.00 -100.00
12-27 13G/A EcoR1 Capital, LLC 10.50 28.68

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2023-11-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S
2023-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)

Similar Companies
ABCL – AbCellera Biologics Inc. ABOS – Acumen Pharmaceuticals, Inc.
ABUS – Arbutus Biopharma Corporation ACAD – ACADIA Pharmaceuticals Inc.
ACLX – Arcellx, Inc.


Financial data and stock pages provided by
Fintel.io

Finpedia: Mirati Therapeutics